Latest revenue
$169.1M
as of 2025-09-30
Latest net income
$17.3M
as of 2025-09-30
Net margin
10.2%
as of 2025-09-30
Community sentiment
Where do you think FOLD is heading?
Keep private notes on FOLD — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
FOLD vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $4.55B
- Enterprise value
- $4.74B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 16.60×
- Dividend yield
- 0.0%
- 52-wk high
- $14.50
- 52-wk low
- $5.51
- Beta
- —
- Shares out
- 314.0M
What this company does
Item 1. BUSINESS Overview We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We seek to deliver the highest quality therapies that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. Our two marketed therapies are Galafold®, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti™ + Opfolda™, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. Galafold® (also referred to as…
AI summary unavailable — showing raw filing excerpt
Generated from FOLD's filing dated 2024-02-28
Key risks
Table of Contents ITEM 1A. RISK FACTORS You should carefully consider these risk factors, together with all of the other information included in this Annual Report on Form 10-K, including our Consolidated Financial Statements and the related notes thereto, before you decide whether to make an investment in our securities. The risks set forth below are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, prospects, financial condition, cash flows, liquidity, funds from operations, results of operations, stock price and ability to service our indebtedness. In…
AI summary unavailable — showing raw filing excerpt
Generated from FOLD's filing dated 2024-02-28
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.